drugset
drugset / Trial / NCT03672643

Long Term Safety Observation of Crizotinib in Chinese NSCLC Population

NCT03672643 ↗

Phase 4 Terminated 41 enrolled Pfizer
NaSingle-groupOpen-labelTreatment

Summary

This study is to allow access to crizotinib who were treated in previous Pfizer-sponsored studies in China.

Timeline

Start
2019-01-28
Primary completion
2023-09-28
Completion
2023-09-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Crizotinib Small molecule — Oral

Indications

No indication recorded.